January 2006
Worldwide Biotech;Jan2006, Vol. 18 Issue 1, p1
Trade Publication
The article reports on the launch of a Phase IIb combination therapy clinical trial of celgosivir by Migenix Inc. which aimed to develop a treatment of chronic hepatitis C virus as of January 2006. Migenix CEO Jim DeMesa offered a statement on the drug. The study is an evaluation of the drug in various treatment arms of patients with chronic hepatitis C virus. It is supported in part through an agreement with Schering-Plough.


Related Articles

  • Serious Doubts on Safety and Efficacy of CCR5 Antagonists. Horster, S.; Goebel, F. // Infection;Apr2006, Vol. 34 Issue 2, p110 

    The article reports on the separate clinical trials involving CCR5 antagonists, GlaxoSmithKline's aplaviroc, Pfizer's maraviroc and Schering-Plough's vicriviroc, in patients with AIDS. In healthy volunteers, the substances exhibited an efficacy to prevent the propagation of virus strains with...

  • Vertex Stock Slides On Schering's Positive Data.  // Bioworld Week;10/22/2007, Vol. 15 Issue 43, p5 

    The article reports that the shares of Vertex Pharmaceuticals Inc. of Cambridge, Massachusetts has dropped by 13.2% due to Phase II clinical trial data from Kenilworth, New Jersey-based Schering-Plough Corp.'s oral hepatitis C protease inhibitor. Schering's boceprevir combined with Pegintron and...

  • New treatments for genotype I chronic hepatitis C - focus on simeprevir. Kanda, Tatsuo; Nakamoto, Shingo; Wu, Shuang; Yokosuka, Osamu // Therapeutics & Clinical Risk Management;2014, Vol. 10, p387 

    Chronic hepatitis C virus (HCV) infection causes end-stage liver diseases and hepatocellular carcinoma. In the USA, Canada, and Japan, simeprevir - one of the second -generation HCV NS3/4A protease inhibitors - in combination with peginterferon а-2a or 2b plus ribavirin has recently been...

  • Combination Therapy with Efavirenz, Nelfinavir, and Nucleoside Reverse-Transcriptase Inhibitors in Children Infected with Human Immunodeficiency Virus Type 1. Starr, Stuart E.; Fletcher, Courtney V.; Spector, Stephen A.; Yong, Florence H.; Fenton, Terence; Brundage, Richard C.; Manion, Douglas; Ruiz, Nancy M.; Gersten, Merril; Becker, Mark; McNamara, James; Purdue, Lynette; Siminski, Suzanne; Graham, Bobbie; Kornhauser, David M.; Fiske, William; Vincent, Carol; Lischner, Harold W.; Dankner, Wayne M.; Flynn, Patricia M. // New England Journal of Medicine;12/16/99, Vol. 341 Issue 25, p1874 

    Background: Consistent long-term viral suppression has been difficult to achieve in children with human immunodeficiency virus type 1 (HIV-1) infection. We tested the safety and antiviral efficacy of a novel combination consisting of efavirenz, nelfinavir, and one or more nucleoside...

  • Recent Advances in Hepatitis C Virus Treatment: Review of HCV Protease Inhibitor Clinical Trials. Chary, Aarthi; Holodniy, Mark // Reviews on Recent Clinical Trials;Sep2010, Vol. 5 Issue 3, p158 

    Hepatitis C virus (HCV) infection affects millions of people world-wide, and chronic infection can result in end-stage liver disease and hepatocellular carcinoma. Conventional therapy to date has involved combination antiviral therapy including alpha-interferon and ribavirin; response rates with...

  • Hepatitis C in the interferon-free era. Streinu-Cercel, Adrian // Germs;Dec2013, Vol. 3 Issue 4, p114 

    The editor discusses the in-depth study of the genetic structure of hepatitis C virus (HCV) which described the viral life cycle and the ideal targets for direct-acting antivirals (DAAs). Topics discussed include enzymatic targets for antivirals attacks, viral proteins role in establishing...

  • Anti-infectives: New oral HCV drug shows promise. Man Tsuey Tse // Nature Reviews Microbiology;Jul2010, Vol. 8 Issue 7, p464 

    The article reports on a study which demonstrated the potent antiviral effects of BMS-790052, a new first-in-class compound for hepatitis C virus (HCV) infection. The drug was evaluated in a Phase I clinical trial of patients chronically infected with HCV. The results suggest that the agent...

  • How INFORM-1 May Change HCV Drug Development. Morrison, Trista // BioWorld Financial Watch;5/4/2009, Vol. 17 Issue 18, p1 

    The article discusses preliminary data on INFORM-1, the first study to combine two direct-acting antivirals for hepatitis C, which was presented at the 44th annual meeting of the European Association for the Study of the Liver (EASL). The encouraging outcomes of the trial are identified, such as...

  • EASL Roundup.  // BioWorld Today;4/27/2009, Vol. 20 Issue 79, p3 

    The article reports on the positive results from a Phase 1b single-agent study of oral antiviral drug, candidate, SCY-365, a cyclophilin inhibitor from Scynexis Inc. in adult patients with genotype 1 chronic hepatitis C virus (HCV). SCY-635 was said to be well tolerated with no serious adverse...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics